September 1, 2017 07:14 AM EDT
Pharma

Neu­ro­tox­i­c­i­ty kills a CAR-T ri­val pushed by J&J, Macro­Gen­ics in $700M deal

John Carroll

Editor & Founder

Back in late 2014, Macro­Gen­ics $MGNX CEO Scott Koenig tout­ed the po­ten­tial of his bis­pe­cif­ic CD19/CD3 drug for B-cell ma­lig­nan­cies, claim­ing MGD011 (du­vor­tux­izum­ab) looked like …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times